References
Antibodies reverse type 1 diabetes in new immunotherapy study
http://www.breakthroughdigest.com/medical-news/antibodies-reverse-type-1-diabetes-in-new-immunotherapy-study/
Belghith, M., Bluestone, J. A., Barriot, S., Mégret, J., Bach, J. F., & Chatenoud, L. (2003). TGF-β-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nature Medicine, 9(9), 1202-1208.
Chatenoud, L., Primo, J., & Bach, J. F. (1997). CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. The Journal of Immunology, 158(6), 2947-2954.
El-Sheikh A, Suarez-Pinzon WL, Power RF, Rabinovitch A (1999). Both CD4(+)and CD8(+)T cells are required for IFN-gamma gene expression in pancreatic islets and autoimmune diabetes development in biobreeding rats. Journal of autoimmunity 12(2): 109-119.
Enee, E., Kratzer, R., Arnoux, J. B., Barilleau, E., Hamel, Y., Marchi, C., et. al. (2012). ZnT8 is a major CD8+ T cell-recognized autoantigen in pediatric type 1 diabetes. Diabetes 61(7): 1779-1784.
Faideau, B., Larger, E., Lepault, F., Carel, J. C., & Boitard, C. (2005). Role of beta-cells in type 1 diabetes pathogenesis. Diabetes 54 Suppl 2: S87-96.
Gillespie, K. M. (2006). Type 1 diabetes: pathogenesis and prevention. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 175(2): 165-170.
Herold, K. C., Hagopian, W., Auger, J. A., Poumian-Ruiz, E., Taylor, L., Donaldson, D., . . . Zivin, R. A. (2002). Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. New England Journal of Medicine, 346(22), 1692-1698.
Keymeulen, B., Vandemeulebroucke, E., Ziegler, A. G., Mathieu, C., Kaufman, L., Hale, G., . . . Candon, S. (2005). Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. New England Journal of Medicine, 352(25), 2598-2608.
Kronenberg, D., Knight, R. R., Estorninho, M., Ellis, R. J., Kester, M. G., de Ru, A., et al. (2012). Circulating preproinsulin signal peptide-specific CD8 T cells restricted by the susceptibility molecule HLA-A24 are expanded at onset of type 1 diabetes and kill beta-cells. Diabetes. 61(7): 1752-1759.
Sherry, N., Hagopian, W., Ludvigsson, J., Jain, S. M., Wahlen, J., Ferry, R. J., . . .Carlin, D. (2011). Teplizumab for treatment of type 1 diabetes (protege study): 1-year results from a randomised, placebo-controlled trial. The Lancet, 378(9790), 487-497.
Torpy, J. M., Lynm, C., Glass, R. M. (2007). JAMA patient page. Type 1 diabetes. JAMA : the journal of the American Medical Association 298(12): 1472.
Yi, Z., Diz, R., Martin, A. J., Morillon, Y. M., Kline, D. E., Li, L., Wang, B., & Tisch, R. (2012). Long-term remission of Diabetes in NOD mice is induced by nondepleting Anti-CD4 and Anti-CD8 antibodies. Diabetes, 61(10), 1-10
Yoon, J.-W. and H.-S. Jun (2005). Autoimmune destruction of pancreatic beta cells. American Journal of Therapeutics 12(6): 580-591.
http://www.breakthroughdigest.com/medical-news/antibodies-reverse-type-1-diabetes-in-new-immunotherapy-study/
Belghith, M., Bluestone, J. A., Barriot, S., Mégret, J., Bach, J. F., & Chatenoud, L. (2003). TGF-β-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nature Medicine, 9(9), 1202-1208.
Chatenoud, L., Primo, J., & Bach, J. F. (1997). CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. The Journal of Immunology, 158(6), 2947-2954.
El-Sheikh A, Suarez-Pinzon WL, Power RF, Rabinovitch A (1999). Both CD4(+)and CD8(+)T cells are required for IFN-gamma gene expression in pancreatic islets and autoimmune diabetes development in biobreeding rats. Journal of autoimmunity 12(2): 109-119.
Enee, E., Kratzer, R., Arnoux, J. B., Barilleau, E., Hamel, Y., Marchi, C., et. al. (2012). ZnT8 is a major CD8+ T cell-recognized autoantigen in pediatric type 1 diabetes. Diabetes 61(7): 1779-1784.
Faideau, B., Larger, E., Lepault, F., Carel, J. C., & Boitard, C. (2005). Role of beta-cells in type 1 diabetes pathogenesis. Diabetes 54 Suppl 2: S87-96.
Gillespie, K. M. (2006). Type 1 diabetes: pathogenesis and prevention. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 175(2): 165-170.
Herold, K. C., Hagopian, W., Auger, J. A., Poumian-Ruiz, E., Taylor, L., Donaldson, D., . . . Zivin, R. A. (2002). Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. New England Journal of Medicine, 346(22), 1692-1698.
Keymeulen, B., Vandemeulebroucke, E., Ziegler, A. G., Mathieu, C., Kaufman, L., Hale, G., . . . Candon, S. (2005). Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. New England Journal of Medicine, 352(25), 2598-2608.
Kronenberg, D., Knight, R. R., Estorninho, M., Ellis, R. J., Kester, M. G., de Ru, A., et al. (2012). Circulating preproinsulin signal peptide-specific CD8 T cells restricted by the susceptibility molecule HLA-A24 are expanded at onset of type 1 diabetes and kill beta-cells. Diabetes. 61(7): 1752-1759.
Sherry, N., Hagopian, W., Ludvigsson, J., Jain, S. M., Wahlen, J., Ferry, R. J., . . .Carlin, D. (2011). Teplizumab for treatment of type 1 diabetes (protege study): 1-year results from a randomised, placebo-controlled trial. The Lancet, 378(9790), 487-497.
Torpy, J. M., Lynm, C., Glass, R. M. (2007). JAMA patient page. Type 1 diabetes. JAMA : the journal of the American Medical Association 298(12): 1472.
Yi, Z., Diz, R., Martin, A. J., Morillon, Y. M., Kline, D. E., Li, L., Wang, B., & Tisch, R. (2012). Long-term remission of Diabetes in NOD mice is induced by nondepleting Anti-CD4 and Anti-CD8 antibodies. Diabetes, 61(10), 1-10
Yoon, J.-W. and H.-S. Jun (2005). Autoimmune destruction of pancreatic beta cells. American Journal of Therapeutics 12(6): 580-591.
T.N. Budi A.N. Khuong C. April | Copyright ©2012